Navigation Links
Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Date:12/22/2015

SAN DIEGO, Dec. 22, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL). HBI-8000 is a novel class I-selective oral histone deacetylase (HDAC) inhibitor with immunomodulatory effects regulating antitumor activity, as well as repression of genes associated with drug resistance. The product is currently completing a Phase 1 open-label, dose escalation trial in Japan to evaluate the safety and pharmacokinetics of HBI-8000 in Japanese patients with non‑Hodgkin's lymphoma (NHL). The orphan drug designation was based on the estimated size of the Japanese PTCL patient population, the non-clinical and clinical studies as well as the clinical development plan in Japan.

"The breadth of activity of HBI-8000 is now emerging strongly as more studies are conducted. The orphan drug designation for PTCL is an important demonstration of efficacy to combat a devastating unmet need," said Dr. Mireille Gillings, Founder, CEO & Executive Chair of HUYA. "With the orphan drug designation, HBI-8000 should benefit from a priority review for marketing authorization and a 10-year market exclusivity as well as financial incentives."

Under the Tripartite Cooperation Treaty between China, South Korea and Japan and given the recent approval of the drug for the treatment of PTCL in China, HUYA launched development of HBI-8000 in Japan for NHL. The Company plans to begin a Phase 2 registration trial in 2016 based on the Pharmaceutical and Medical Devices Agency's (PMDA) acceptance of HUYA's accelerated development strategy for Japan.

About Peripheral T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) represents an aggressive subset of non-Hodgkin's lymphomas (NHLs) that encompasses a broad range of diverse but rare mature lymphomas of T-cell or NK-cell origin.  Regardless of subtype, cases of PTCL share aggressive clinical behavior, refractoriness to conventional chemotherapy, and poor overall prognoses.  In Japan, the incidence of PTCL is approximately 25% of all malignant lymphomas.  According to the most recent patient statistical survey conducted by Japan's Ministry of Health, Labour and Welfare (MHLW), the number of patients with malignant lymphoma is estimated at approximately 55,000, with an estimated PTCL number of about 14,000 patients.  Treatment advances in PTCL have been slow compared to other lymphomas and relapse occurs after treatment with most of the current therapies, with few effective options for salvage therapies. 

About HBI-8000
HBI-8000 is a member of the benzamide class of histone deacetylase (HDAC) inhibitors designed to block the catalytic pocket of Class I HDACs.  HBI-8000 is an orally bioavailable, low-nanomolar inhibitor of cancer-associated HDAC enzymes with favorable pharmacology and safety profiles. HBI-8000 inhibits cancer-associated Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10 at nanomolar concentrations and stimulates accumulation of acetylated histones H3 and H4 in tumor cells. Studies with human-derived tumor cell lines have demonstrated that HBI-8000 inhibits the growth of many tumor cell lines via multiple mechanisms of action, including epigenetic regulation of tumor cell growth and apoptosis, immunomodulatory effects regulating antitumor activity, as well as repression of genes associated with drug resistance.  To date, HBI-8000 has been dosed in various types of hematological and solid tumors in several clinical trials, including a Phase 1 trial completed in the United States.

About HUYA Bioscience International
HUYA is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally.   HUYA was awarded the Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category and a Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit www.huyabio.com

Contact details:
Yiota Merianos
HUYA Corporate Communications
+1.858.353.1217
ymerianos@huyabio.com

 


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
3. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
4. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
5. Northstar Biosciences Launches All Natural Skincare Solutions
6. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
7. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
8. Seahorse Bioscience Announces AACR Travel Award Recipients
9. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
10. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
11. Nanotechnologies in Bioscience, Live Webinar on May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 ... of three scientists, Jacques Dubochet, Joachim Frank ... developments in cryo-electron microscopy (cryo-EM) have ... within the structural biology community. The winners worked ... can now routinely produce highly resolved, three-dimensional images ...
(Date:10/6/2017)... D.C. (PRWEB) , ... October 06, 2017 , ... ... will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical ... Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the ...
(Date:10/5/2017)... , ... October 05, 2017 , ... Understanding the microbiome, ... frontiers in human health. Gut Love: You Are My Future, the newest exhibit on ... perspective as it explores the human condition through the lens of the gut microbiome. ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
Breaking Biology News(10 mins):